Developer docs
API playgroundTry for free, no card

Search company profiles

Amgen Ventures

Full company profile

uuid0002kc9

Namestring
Amgen Ventures
Legal namestring
Amgen Inc.
Websiteurl
amgenbd.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. (NASDAQ: AMGN), a fully-integrated biotechnology company. Headquartered within Amgen's Thousand Oaks, California campus with an additional presence in South San Francisco, the unit operates with 11-50 employees and pursues partnerships, equity investments, acquisitions, out-licensing arrangements, and academic alliances across the therapeutic areas of oncology, inflammation, general medicine, and rare disease. The entity was established as a formalized business development function in 2014 under the Amgen BD brand (amgenbd.com).

The unit's product surface is structured around five deal archetypes: venture investments (e.g., AAVantgarde Bio $141 million Series B in November 2025; Ember LifeSciences $27 million Series A in May 2026), strategic co-development collaborations (e.g., AstraZeneca's tezepelumab since 2012; BeiGene oncology alliance since 2019 valued at $2.7 billion for a 20.5% equity stake), in-licensing transactions (e.g., Arrowhead Pharmaceuticals' RNAi ARC-LPA cardiovascular program since 2016), out-licensing and spin-outs of internal assets (e.g., Vigil Neuroscience's TREM2 program in 2020), and academic research partnerships (Broad Institute, MIT, UCSF, Caltech, UCLA, University of Washington Institute for Protein Design, and Mila — Quebec AI Institute). Amgen Inc. has separately executed major acquisitions including ChemoCentryx, deCODE, Five Prime, Horizon, Micromet, Nuevolution, and Onyx.

The business model is not revenue-generating in the conventional sense; Amgen Ventures deploys capital from Amgen Inc.'s balance sheet and functions as a strategic deal-making engine rather than a fee-earning venture fund. It operates without third-party LP capital, does not charge management fees, and does not disclose standalone revenue. Value capture for the parent company comes through pipeline augmentation, geographic expansion (notably China via BeiGene), technology sourcing, and optionality on emerging modalities such as gene therapy, RNAi therapeutics, and generative biology.

Short descriptiontext

Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. (NASDAQ: AMGN), executing equity investments, co-development partnerships, in-licensing, out-licensing, and academic alliances in oncology, inflammation, general medicine, and rare disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersThousand Oaks, United States
HQ citystring
Thousand Oaks
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech venture capital, pharmaceutical business development, drug development partnerships, biotech equity investments, therapeutic out-licensing
Industry1 code
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Biotech Venture Capital and Business Development
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Amgen BD
Description

The branded identity for Amgen's business development and partnering activities, accessible via amgenbd.com

amgenbd.com
Core offering1 text field

Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. It invests equity capital in early- and late-stage biotechnology companies and structures co-development, co-commercialization, acquisition, and out-license arrangements with biotech innovators and academic research institutions. The unit's mandate spans oncology, inflammation, general medicine, and rare disease therapeutics, leveraging Amgen's integrated discovery-through-commercialization capabilities.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Amgen Business Development operates as a fully-integrated biotechnology partnership platform, offering multiple investment and collaboration structures rather than a unified product. The core offerings include Venture Investments (for early-stage biotech companies), Collaborations (co-development agreements), Acquisitions, Out-License and Spin-Outs (for asset externalization), Academic Partnerships (with research institutions), and Companion Diagnostics partnerships. Amgen supports the full life-cycle of drug development from human genetics and target validation through global commercialization, with therapeutic focus areas in oncology, inflammation, general medicine, and rare disease. Notable investment targets include Ember LifeSciences (cold chain logistics), AAVantgarde Bio (gene therapy), Strand Therapeutics (mRNA therapeutics), and Cartography Biosciences (antibody-based oncology).

Product and service6 records
1Venture Investments
CategoryInvestment Vehicle
Description

Strategic equity investments in early- and late-stage biotechnology companies developing novel therapeutics and platform technologies aligned with Amgen's focus areas (oncology, inflammation, general medicine, rare disease). For biotech founders and CSOs seeking corporate venture capital.

2Collaborations
CategoryPartnership Structure
Description

Co-development and co-commercialization partnerships with biotech innovators for joint advancement of therapeutic programs. Includes strategic collaborations such as AstraZeneca's tezepelumab co-development. For biotech companies seeking a development and commercialization partner.

3Acquisitions
CategoryInvestment Structure
Description

Strategic acquisitions of biotech companies with technologies and pipelines that complement Amgen's focus areas. Acquired entities include ChemoCentryx, deCODE, Five Prime, Horizon, KAI, Micromet, Nuevolution, Onyx, Otezla, and Rodeo. For biotech companies and shareholders seeking an exit and large-scale integration.

4Out-License and Spin-Outs
CategoryInvestment Structure
Description

Out-licensing and spin-out arrangements through which Amgen transfers internal assets or programs to dedicated companies (Akero, Bioage, Celimmune, Jasper, Kartos, Neumora, Vigil Neuroscience, Volastra, Voravi) for focused development. For external partners and biotech founders seeking assets and capital.

5Academic Partnerships
CategoryResearch Collaboration
Description

Sponsored research and drug discovery collaborations with premier academic and research institutions including Broad Institute, Caltech, MIT, UCLA, UCSF, University of Washington Institute for Protein Designs, and Mila - Quebec AI Institute. For academic researchers and technology transfer offices seeking industry partnership.

6Companion Diagnostics
CategoryPartnership Structure
Description

Partnerships for companion diagnostics development alongside Amgen therapeutics with diagnostics developers including Adaptive, AmoyDx, Dako/Agilent, Foundation Medicine, Guardant Health, Qiagen, and Roche/Ventana. For diagnostic developers seeking a therapeutic anchor and for enabling precision medicine for Amgen's pipeline.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Amgen out-licensed TREM2 programs to Vigil Neuroscience, a newly formed company co-founded and incubated by Atlas Venture. Vigil launched with $50 million Series A financing to progress TREM2 programs for neurodegenerative diseases.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Amgen entered a strategic collaboration with BeiGene in 2019, investing $2.7 billion for a 20.5% stake. BeiGene commercializes XGEVA, KYPROLIS, and BLINCYTO in China. The companies collaborate on advancing Amgen's oncology pipeline, sharing global R&D costs with BeiGene contributing up to $1.25 billion alongside Amgen's investments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Amgen entered licensing agreements with Arrowhead to develop RNAi therapies for cardiovascular disease. Amgen received exclusive worldwide license to Arrowhead's RNAi ARC-LPA program targeting elevated lipoprotein(a), plus option for an undisclosed cardiovascular target.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2012-01-01
Description

Amgen and AstraZeneca jointly develop and commercialize monoclonal antibodies including tezepelumab. AstraZeneca made a $50 million upfront payment with shared costs and profits. The partnership evolved to define each partner's roles for launch and commercialization.

5Nuevolution
Strategic tierCoreTypeStrategic or Co-development Partner
Description

A long-term collaboration that led to acquisition, expanding Amgen's ability to discover novel small molecules.

amgenbd.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration for RNA-targeted small molecule therapies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic collaboration for generative biology and protein generation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership for research collaboration in drug discovery.

9MIT
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership for life sciences research.

amgenbd.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership for biomedical research collaboration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Eli Lilly's venture arm with strong Asia/China focus. Comparable to Amgen Ventures' BeiGene-driven Asia strategy and biotech CVC model, though more regionally focused.

TypeDirect peer
Description

Pfizer's corporate venture capital arm making minority equity investments in biotech companies. Similar to Amgen Ventures in deploying strategic capital to source external innovation aligned with Pfizer's therapeutic priorities.

TypeDirect peer
Description

Corporate venture capital arm of Novartis investing in biotech and life sciences. Closely comparable model to Amgen Ventures: pharma parent, therapeutic-aligned investing, focused on building pipeline optionality through early-stage equity.

TypeDirect peer
Description

Roche's corporate venture arm investing in early- and late-stage biotech. Directly comparable to Amgen Ventures as both are pharma CVCs deploying strategic capital into therapeutics aligned with their parent's pipeline.

TypeDirect peer
Description

Merck's CVC arm investing across therapeutics, digital health, and life sciences tools. Directly comparable as a major pharma CVC with similar mandate to source external innovation through equity investments.

6Bristol-Myers Squibb Strategic Investments
TypeDirect peer
Description

BMS's CVC activity investing in biotech to support its oncology and specialty pipeline. Comparable as a major pharma CVC with similar therapeutic-area-driven investing mandate.

TypeDirect peer
Description

Sanofi's CVC arm investing in early-stage biotech and digital health. Comparable to Amgen Ventures in pharma CVC structure, therapeutic-area-aligned investing, and ability to leverage parent's commercialization infrastructure.

TypeBroad incumbent
Description

J&J's broader innovation arm including JLABS incubator and JJDC venture investing. Comparable as a pharma corporate innovation platform, though broader in scope including incubators and accelerators.

TypeDirect peer
Description

AbbVie's corporate venture capital arm investing in emerging biotech. Comparable to Amgen Ventures in being a top-10 pharma CVC focused on therapeutic-area-aligned equity investing to support parent pipeline.

TypeDirect peer
Description

GSK's biotech-focused venture arm. Comparable to Amgen Ventures as a pharma CVC deploying capital in early-stage biotech aligned with parent therapeutic priorities.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment137 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amgen Ventures

Biotech Venture Capital and Business Developmentamgenbd.com

Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. (NASDAQ: AMGN), executing equity investments, co-development partnerships, in-licensing, out-licensing, and academic alliances in oncology, inflammation, general medicine, and rare disease.

What Amgen Ventures does

Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. (NASDAQ: AMGN), a fully-integrated biotechnology company. Headquartered within Amgen's Thousand Oaks, California campus with an additional presence in South San Francisco, the unit operates with 11-50 employees and pursues partnerships, equity investments, acquisitions, out-licensing arrangements, and academic alliances across the therapeutic areas of oncology, inflammation, general medicine, and rare disease. The entity was established as a formalized business development function in 2014 under the Amgen BD brand (amgenbd.com).

The unit's product surface is structured around five deal archetypes: venture investments (e.g., AAVantgarde Bio $141 million Series B in November 2025; Ember LifeSciences $27 million Series A in May 2026), strategic co-development collaborations (e.g., AstraZeneca's tezepelumab since 2012; BeiGene oncology alliance since 2019 valued at $2.7 billion for a 20.5% equity stake), in-licensing transactions (e.g., Arrowhead Pharmaceuticals' RNAi ARC-LPA cardiovascular program since 2016), out-licensing and spin-outs of internal assets (e.g., Vigil Neuroscience's TREM2 program in 2020), and academic research partnerships (Broad Institute, MIT, UCSF, Caltech, UCLA, University of Washington Institute for Protein Design, and Mila — Quebec AI Institute). Amgen Inc. has separately executed major acquisitions including ChemoCentryx, deCODE, Five Prime, Horizon, Micromet, Nuevolution, and Onyx.

The business model is not revenue-generating in the conventional sense; Amgen Ventures deploys capital from Amgen Inc.'s balance sheet and functions as a strategic deal-making engine rather than a fee-earning venture fund. It operates without third-party LP capital, does not charge management fees, and does not disclose standalone revenue. Value capture for the parent company comes through pipeline augmentation, geographic expansion (notably China via BeiGene), technology sourcing, and optionality on emerging modalities such as gene therapy, RNAi therapeutics, and generative biology.

Amgen Ventures firmographics

Firmographics
Name
Amgen Ventures
Legal name
Amgen Inc.
Website
https://amgenbd.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
10,001+ employees
Short description
Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. (NASDAQ: AMGN), executing equity investments, co-development partnerships, in-licensing, out-licensing, and academic alliances in oncology, inflammation, general medicine, and rare disease.
Ownership category
akta.pro rank

Amgen Ventures industry classification

Industry
Product category
Biotech Venture Capital and Business Development
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms

Keywords

  • Biotech venture capital
  • Pharmaceutical business development
  • Drug development partnerships
  • Biotech equity investments
  • Therapeutic out-licensing

Where Amgen Ventures is headquartered

Location

Headquarters

HQ city
Thousand Oaks
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Amgen Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others

Distribution channels1 record

Marketing channels2 records

Amgen Ventures product offering

Product offering

Core offering

Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. It invests equity capital in early- and late-stage biotechnology companies and structures co-development, co-commercialization, acquisition, and out-license arrangements with biotech innovators and academic research institutions. The unit's mandate spans oncology, inflammation, general medicine, and rare disease therapeutics, leveraging Amgen's integrated discovery-through-commercialization capabilities.

Product overview

Amgen Business Development operates as a fully-integrated biotechnology partnership platform, offering multiple investment and collaboration structures rather than a unified product. The core offerings include Venture Investments (for early-stage biotech companies), Collaborations (co-development agreements), Acquisitions, Out-License and Spin-Outs (for asset externalization), Academic Partnerships (with research institutions), and Companion Diagnostics partnerships. Amgen supports the full life-cycle of drug development from human genetics and target validation through global commercialization, with therapeutic focus areas in oncology, inflammation, general medicine, and rare disease. Notable investment targets include Ember LifeSciences (cold chain logistics), AAVantgarde Bio (gene therapy), Strand Therapeutics (mRNA therapeutics), and Cartography Biosciences (antibody-based oncology).

Differentiator

Problem solved

Functional benefit

Brands

  • Amgen BD: The branded identity for Amgen's business development and partnering activities, accessible via amgenbd.com

Products and services

  • Venture Investments Strategic equity investments in early- and late-stage biotechnology companies developing novel therapeutics and platform technologies aligned with Amgen's focus areas (oncology, inflammation, general medicine, rare disease). For biotech founders and CSOs seeking corporate venture capital.
  • Collaborations Co-development and co-commercialization partnerships with biotech innovators for joint advancement of therapeutic programs. Includes strategic collaborations such as AstraZeneca's tezepelumab co-development. For biotech companies seeking a development and commercialization partner.
  • Acquisitions Strategic acquisitions of biotech companies with technologies and pipelines that complement Amgen's focus areas. Acquired entities include ChemoCentryx, deCODE, Five Prime, Horizon, KAI, Micromet, Nuevolution, Onyx, Otezla, and Rodeo. For biotech companies and shareholders seeking an exit and large-scale integration.
  • Out-License and Spin-Outs Out-licensing and spin-out arrangements through which Amgen transfers internal assets or programs to dedicated companies (Akero, Bioage, Celimmune, Jasper, Kartos, Neumora, Vigil Neuroscience, Volastra, Voravi) for focused development. For external partners and biotech founders seeking assets and capital.
  • Academic Partnerships Sponsored research and drug discovery collaborations with premier academic and research institutions including Broad Institute, Caltech, MIT, UCLA, UCSF, University of Washington Institute for Protein Designs, and Mila - Quebec AI Institute. For academic researchers and technology transfer offices seeking industry partnership.
  • Companion Diagnostics Partnerships for companion diagnostics development alongside Amgen therapeutics with diagnostics developers including Adaptive, AmoyDx, Dako/Agilent, Foundation Medicine, Guardant Health, Qiagen, and Roche/Ventana. For diagnostic developers seeking a therapeutic anchor and for enabling precision medicine for Amgen's pipeline.

Companies that use Amgen Ventures

Customer profile

Segments2 records

Ideal customer profiles2 records

Amgen Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Amgen Ventures partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

  • Vigil NeurosciencecoreStrategic or Co-development Partner · 1 January 2020Amgen out-licensed TREM2 programs to Vigil Neuroscience, a newly formed company co-founded and incubated by Atlas Venture. Vigil launched with $50 million Series A financing to progress TREM2 programs for neurodegenerative diseases.
  • BeiGeneflagshipStrategic or Co-development Partner · 1 January 2019Amgen entered a strategic collaboration with BeiGene in 2019, investing $2.7 billion for a 20.5% stake. BeiGene commercializes XGEVA, KYPROLIS, and BLINCYTO in China. The companies collaborate on advancing Amgen's oncology pipeline, sharing global R&D costs with BeiGene contributing up to $1.25 billion alongside Amgen's investments.
  • Arrowhead PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2016Amgen entered licensing agreements with Arrowhead to develop RNAi therapies for cardiovascular disease. Amgen received exclusive worldwide license to Arrowhead's RNAi ARC-LPA program targeting elevated lipoprotein(a), plus option for an undisclosed cardiovascular target.
  • AstraZenecaflagshipStrategic or Co-development Partner · 1 January 2012Amgen and AstraZeneca jointly develop and commercialize monoclonal antibodies including tezepelumab. AstraZeneca made a $50 million upfront payment with shared costs and profits. The partnership evolved to define each partner's roles for launch and commercialization.
  • NuevolutioncoreStrategic or Co-development PartnerA long-term collaboration that led to acquisition, expanding Amgen's ability to discover novel small molecules.
  • Arrakis TherapeuticsminorStrategic or Co-development PartnerCollaboration for RNA-targeted small molecule therapies.
  • Generate BiomedicinesminorStrategic or Co-development PartnerStrategic collaboration for generative biology and protein generation.
  • Broad InstitutecoreStrategic or Co-development PartnerAcademic partnership for research collaboration in drug discovery.
  • MITcoreStrategic or Co-development PartnerAcademic partnership for life sciences research.
  • UCSFcoreStrategic or Co-development PartnerAcademic partnership for biomedical research collaboration.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Amgen Ventures competitors and assessment

Company assessment

Direct peers

  • Lilly Asia Ventures: Eli Lilly's venture arm with strong Asia/China focus. Comparable to Amgen Ventures' BeiGene-driven Asia strategy and biotech CVC model, though more regionally focused.
  • Pfizer Ventures: Pfizer's corporate venture capital arm making minority equity investments in biotech companies. Similar to Amgen Ventures in deploying strategic capital to source external innovation aligned with Pfizer's therapeutic priorities.
  • Novartis Venture Fund: Corporate venture capital arm of Novartis investing in biotech and life sciences. Closely comparable model to Amgen Ventures: pharma parent, therapeutic-aligned investing, focused on building pipeline optionality through early-stage equity.
  • Roche Venture Fund: Roche's corporate venture arm investing in early- and late-stage biotech. Directly comparable to Amgen Ventures as both are pharma CVCs deploying strategic capital into therapeutics aligned with their parent's pipeline.
  • Merck Global Health Innovation Fund: Merck's CVC arm investing across therapeutics, digital health, and life sciences tools. Directly comparable as a major pharma CVC with similar mandate to source external innovation through equity investments.
  • Bristol-Myers Squibb Strategic Investments: BMS's CVC activity investing in biotech to support its oncology and specialty pipeline. Comparable as a major pharma CVC with similar therapeutic-area-driven investing mandate.
  • Sanofi Ventures: Sanofi's CVC arm investing in early-stage biotech and digital health. Comparable to Amgen Ventures in pharma CVC structure, therapeutic-area-aligned investing, and ability to leverage parent's commercialization infrastructure.
  • AbbVie Ventures: AbbVie's corporate venture capital arm investing in emerging biotech. Comparable to Amgen Ventures in being a top-10 pharma CVC focused on therapeutic-area-aligned equity investing to support parent pipeline.
  • GlaxoSmithKline (SR One): GSK's biotech-focused venture arm. Comparable to Amgen Ventures as a pharma CVC deploying capital in early-stage biotech aligned with parent therapeutic priorities.

Broad incumbents

  • Johnson & Johnson Innovation (JLABS): J&J's broader innovation arm including JLABS incubator and JJDC venture investing. Comparable as a pharma corporate innovation platform, though broader in scope including incubators and accelerators.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

Amgen Ventures social profiles

Digital presence

Amgen Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amgen Ventures leadership team

Management profile

Number of profiles

Profiles2 records

Amgen Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amgen Ventures M&A and investment

M&A and investment

M&A

Investments137 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amgen Ventures

What does Amgen Ventures do?

Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. It invests equity capital in early- and late-stage biotechnology companies and structures co-development, co-commercialization, acquisition, and out-license arrangements with biotech innovators and academic research institutions. The unit's mandate spans oncology, inflammation, general medicine, and rare disease therapeutics, leveraging Amgen's integrated discovery-through-commercialization capabilities.

Is Amgen Ventures a public or private company?

Amgen Ventures is a private company. It is classified as corporate owned and is currently operating.

When was Amgen Ventures founded?

Amgen Ventures was founded in 2014. It employs 10,001+ people.

Where is Amgen Ventures based?

Amgen Ventures is headquartered in Thousand Oaks, United States, in the North America region.

Who are Amgen Ventures's main competitors?

Direct peers on record are Lilly Asia Ventures, Pfizer Ventures, Novartis Venture Fund, Roche Venture Fund, Merck Global Health Innovation Fund, Bristol-Myers Squibb Strategic Investments, Sanofi Ventures, AbbVie Ventures and GlaxoSmithKline (SR One). Johnson & Johnson Innovation (JLABS) is listed as a broad incumbent.

Does Amgen Ventures have an API?

No public API is recorded for Amgen Ventures.

What industry is Amgen Ventures in?

Amgen Ventures's product category is Biotech Venture Capital and Business Development. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterBigHat BiosciencesBigHat Biosciences closed a $75 million Series C in September 2026, bringing total funding to $223 million. Its lead asset, BHB810, a CDH17-directed antibody-drug conjugate, has dosed its first patient in a Phase I/II study for gastrointestinal cancers. The company plans to use the funds for clinical development of BHB810 and BHB299.FinSMEsBigHat Biosciences Raises $75M in Series C FinancingBigHat Biosciences closed a $75M Series C, bringing total funding to $223M. The funds will advance its AI-designed therapeutics, including BHB810 and BHB299, with BHB299 trials planned for 2027.Pulse 2.0Ember LifeSciences: $27 Million Series A Boosted By Amgen Ventures And TDF VenturesEmber LifeSciences announced additional strategic investments from Amgen Ventures and TDF Ventures, bringing its total Series A funding to $27 million, following a previously announced financing round led by Sea Court Capital. The funding will support rapid scaling of the company's Ember Cube 2 cold chain logistics platform and further expansion of its global footprint. The Ember Cube 2 platform was recently recognized with a "Best of the Best" distinction from the Red Dot Award for product design.Venture Capital Access OnlineEmber LifeSciences announces new strategic investments boosting Series A to $27MEmber LifeSciences announced strategic investments from Amgen Ventures and TDF Ventures, bringing its Series A funding to $27 million. The company also announced full commercial availability of the Ember Cube 2, a reusable cold chain solution. Financial terms were not disclosed.VC News DailyEmber LifeSciences Inks $10.5M Addtional Series A FundingEmber LifeSciences announced strategic investments from Amgen Ventures and TDF Ventures. The company, a provider of cold chain technology, received these investments from the corporate venture arm of Amgen and a venture capital firm focused on enterprise-focused technology.FinSMEsEmber LifeSciences Expand Series A to $27MEmber LifeSciences raised an undisclosed amount in Series A extension funding led by Amgen Ventures and TDF Ventures, bringing the total to $27M. The company will use the funds to expand operations and development efforts. It develops reusable digital shipping containers for cold-chain logistics.BioSpaceStrand Therapeutics Appoints Kunal Bhatia as Chief Financial OfficerStrand Therapeutics appointed Kunal Bhatia as Chief Financial Officer, bringing 15 years of investment banking experience. The appointment follows a $153 million Series B and initial Phase 1 data for STX-001. Bhatia will support the company's clinical entry for STX-003 in mid-2026.FinSMEsAAVantgarde Closes $141M Series B FinancingAAVantgarde Bio, a Milan-based clinical-stage biotechnology company developing therapies for inherited retinal diseases, raised $141 million in Series B funding. The round was led by Schroders Capital with participation from existing investors including Atlas Venture, Forbion, Longwood Fund, and Sofinnova Partners, as well as new investors such as Amgen Ventures, CDP Venture Capital, and XGen Venture. The company intends to use the proceeds to complete clinical proof-of-concept for its AAVB-039 CELESTE study targeting Stargardt disease and its AAVB-081 LUCE phase 1/2 trial for retinitis pigmentosa secondary to Usher 1B.FirstWordAAVantgarde draws $141M series B to advance pair of retinal gene therapiesAAVantgarde Bio closed a $141-million (€122 million) oversubscribed series B financing round co-led by Schroders Capital, Atlas Venture, and Forbion, with participation from fourteen other investors including Amgen Ventures and Sofinnova Partners. The proceeds will fund clinical proof-of-concept trials for two AAV vector gene augmentation programmes: AAVB-039 for Stargardt disease and AAVB-081 for retinitis pigmentosa secondary to Usher syndrome type 1B. The Milan-based company, launched in 2021, previously raised a €61-million series A in 2023.